Madam Therapeutics

News Archive

European Commission publishes our screening-project for peptides to treat COVID-19 and bacterial infections for increased visibility to global investors

In a united spirit to COVID-19 response and to support the European recovery, the European Investment Project Portal (EIPP) and the Commission’s Research Directorate-General (RTD) have again put together their forces and acted as a team to acknowledge COVID-19 projects as a core area of interest for todays’ EU needs.

Various projects have already been selected outstanding projects to tackle the Corona virus and awarded a dedicated Covid-19 certificate.

Madam Therapeutics was one of the limited number of companies that was selected in this competition. The “Turn-The_Tide” project was published on the investment portal

The promoters of these projects have been invited to submit their project for publication on the EIPP to boost their visibility to investors.

The EIPP developed a special Covid-19 tag for these projects to reach out and attract more investors worldwide.

Madam Therapeutics is screening it’s peptide family for activity against the corona virus. We anticipate that this new project is matching the investors’ interests, and will develop into one of our new success stories!

Pharma companies are creating a new $1 billion fund to acquire or invest in small antibiotic companies

Big Pharma exited from the antibiotics space one by one. And now they may be coming back together.

Pfizer, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Bayer Pharmaceuticals, Merck KGaA and the American Merck — one of the last giants standing — are teaming up to create a $1 billion for-profit venture to bet on small biotechs developing mid-stage antibiotics, Ed Silverman reported for STAT.

Government officials from Germany, Sweden, France and the UK, as well as representatives from Wellcome Trust and Pew Charitable Trusts, will join the companies to announce the initiative on July 9, Silverman wrote. The World Health Organization and the European Investment Bank are also involved in what is being billed as a new solution to the “antibiotic innovation challenge.”

As concerns about antibiotic resistance loom ever larger, though, the effort itself may count. “The thinking is that, ideally, if they put money in [the fund], this will serve them in the long run, but also make them look good,” reads a key quote. “They got pretty bad press when they walked out on antibiotics.”

Madam Therapeutics welcomes this very important initiative, and believes this is another sign that pharma and investors are getting back in the field.

Source: Endpointsnews

German scientist warns: ‘the danger of infectious diseases is completely underestimated ‘

German archeo-geneticist Johannes Krause has published a new book entitled “De reis van onze genen” (The journey of our genes). Krause conducts DNA research into infectious diseases that have plagued humanity for thousands of years. If we don’t take it more seriously, he says corona is just the beginning: leprosy, tuberculosis and syphilis are ready for a comeback.

Krause usually looks back to the past, sometimes up to hundreds of thousands of years ago. Armed with revolutionary technology, he deciphers genetic  material from ancient bones, skulls and teeth. From that DNA he derives messages from the past. For example, how our distant ancestors spread across the continents. And what diseases they carried with them.

And how those diseases adapted to their hosts, and vice versa. “We used to try to reconstruct prehistory with modern data,” says Krause in an interview in Dutch newspaper Financiele Dagblad.

In his book he warns about the danger of bacterial diseases such as tuberculosis, syphilis, leprosy, cholera and even plague. They have been quiet for more than a hundred years, but they have certainly not been defeated, says Krause.

“If we are not careful, they will soon be able to return to prosperous parts of the world. The first signs are already there….. “

Source: FD.nl

Remko van Leeuwen interviewed for Dutch TV show “Eén Vandaag” on the problems of start-ups during corona times

Dutch TV news show “Eén Vandaag” viewed by around 1 million people today highlighted the financial challenges of Dutch start-ups during corona times. Remko van Leeuwen is one the CEOs that was interviewed for the program.

During the interview (in Dutch, no subtitles), Remko van Leeuwen talks about the predictability of the next public health crisis: antibiotic resistance. He explained that he and his colleagues have spent the past 9 years developing a new antibiotic. “Hundreds of thousands of people die every year from antibiotic resistance worldwide. If the corona crisis has shown anything, it is that we have been too late to intervene. That is why it is so important to look ahead and start developing new antibiotics now” he explains in the interview. “New investments in the company are needed but that because of the corona outbreak, no one dared to invest”.

Because start-ups often cannot use regular government support to deal with the crisis, the Corona Bridging Loan (COL) from the Dutch government has been set up specifically for this sector. It is a pot of 300 million euros. Entrepreneurs can submit an application to Regional Development Companies (ROMs), which implement this scheme at the request of the cabinet. Our application was rejected. And we are not the only one who got a rejection, Remko explains during the interview.

“It has always been difficult to find investors for the development of new antibiotics”, says Remko van Leeuwen during the interview. “That was also the case for corona. New drugs often remain on the shelf for a long time because doctors want to avoid frequent use and the possible resistance.

But during the corona outbreak, antibiotics are widely used to fight secondary infections. This has increased concerns about resistance, says Van Leeuwen. He thinks that it was not the right choice from the Dutch government not to strengthen our company with an emergency loan. “Yes, maybe I will only make a profit in 5 or 6 years. But that’s how it works, especially in bioscience.”

Along with the other people that are interviewed, Remko therefore makes a plea for more government support to guide start-ups like Madam Therapeutics through the corona crisis.

Antibiotic resistance may rise after COVID-19, as doctors struggle to treat secondary infections. New antibiotics are urgently needed, but development is falling behind.

Mother wearing a green homemade protective face mask and putting one to her daughter at home during the coronavirus Covid-19.

As the Covid-19 pandemic moves across the world, it may drag a second slow-motion pandemic behind it. Even though Covid-19 is a viral illness not affected by antibiotics, early data from hospitals shows that very high proportions of patients—more than 90 percent in some cohorts—are being treated with those drugs to cure or protect against secondary infections during respiratory illnesses or hospitalization. That’s being accompanied by an unmeasured but possibly huge number of people taking antibiotics on their own.

Those parallel phenomena mean that Covid-19 could whomp up antibiotic resistance, pathogens’ adaptive ability to defend themselves against drugs intended to kill them. Resistance is already a crisis: It causes an estimated 700,000 deaths around the world each year, almost four times the death toll from the novel coronavirus so far. Diminishing the power of antibiotics could undermine an important part of the medical response to Covid-19.

“In the context of Covid-19, antibiotics should be considered as important as protective gowns or facemasks,” says Adam Roberts, a microbiologist and antibiotic discoverer at the Liverpool School of Tropical Medicine in an interview with WIRED magazine. “We do not expect healthcare workers to go into hospital situations without the correct protective equipment. Nor should we expect clinics to do their job without the appropriate antibiotics. It is part of our defense for any pandemic situation.”

Madam Therapeutics endorses this view, and therefore works in parallel on the development of new antibiotics, as well as new treatment for the corona virus, both based on it’s peptide based antimicrobial platform.

Source: WIRED magazine

Why Madam Therapeutics focuses on developing its SAAPs as treatment for both the Corona virus as well as superbugs during the COVID-19 crisis

Young woman wearing protective face mask, she sitting in bus transportation in the city.

We’re all focused on the coronavirus, but there’s another, major threat still lurking: superbugs. And the pandemic is a stark reminder of the need to be prepared for public health crises, particularly the growing danger of antibiotic-resistant bacteria, says Pew in new analysis

Fact: We need new antibiotics. Superbugs killed 160,000 Americans in 2010—and unless we take action, they’re expected to kill 10 million people per year by 2050.

But there aren’t enough antibiotics in the development pipeline. “According to Pew’s most recent assessment of the antibiotic pipeline, far too few drugs are in development with even the potential to treat the most dangerous superbugs,” writes Pew

Why are we talking about antibiotics in the context of a virus? “Antibiotics are needed to protect COVID-19 patients who have weakened immune systems (and who may be on ventilators) and are therefore at risk for secondary bacterial infections. Likewise, antibiotics are also critical for patients fighting cancer, receiving dialysis, undergoing surgery, and requiring countless other medical treatments and procedures,” Pew explains.

This is why Madam Therapeutics is developing peptides from it’s SAAP both as antiviral compounds targeted to fight COVID-19, as well as the secondary bacterial infections.

New York Times: The Ganges River in India Brims With Dangerous Bacteria

The Ganges river in India is living proof that antibiotic-resistant bacteria are almost everywhere. The river offers powerful insight into the prevalence and spread of drug-resistant infections, one of the world’s most pressing public health problems. Its waters provide clues to how these pathogens find their way into our ecosystem.

According to the New York Times, annual tests by scientists at the Indian Institute of Technology show that antibiotic-resistant bacteria appear while the river is still flowing through the narrow gorges of the Himalayan foothills, hundreds of miles before it encounters any of the usual suspects that would pollute its waters with resistant germs.

Other studies confirm the danger. An article in Lancet Infectious Diseases found that about 57 percent of infections in India with Klebsiella pneumoniae, a common bacterium, were carbapenem-resistant.

More reading: https://www.nytimes.com/2019/12/23/health/ganges-drug-resistant-bacteria.html and https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30072-0/fulltext

CDC report: every 15 minutes someone in the USA dies of a drug-resistant superbug

Antimicrobial resistance rates are rising with an alarming rate.

Every 15 minutes, someone in the United States now dies of a superbug that has learned to outsmart even our most sophisticated antibiotics, according to a new report from the US Centers for Disease Control and Prevention.That’s about 35,000 deaths each year from drug-resistant infections, according to the landmark report. This is twice the number of deaths since 2013.

People in the United States are misusing antibiotics, study says. The report places five drug-resistant superbugs on the CDC’s “urgent threat” list — two more germs than were on the CDC’s list in 2013, the last time the agency issued a report on antibiotic resistance.

Companies like Madam Therapeutics are developing solutions that could help these patients, but we need to be allowed to use these drugs and get reimbursed appropriately, as otherwise development cannot be paid.

Antibiotic Awareness Week: getting the risk-reward ratio right for R&D to fight superbugs

Each November, World Antibiotic Awareness Week (WAAW) aims to increase global awareness of antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.

During this week, there is heightened attention for the fact that new antibiotics are imperative to overcoming the threat of AMR. Yet approvals for new antibiotics have declined for many years. The last new class of antibiotics was introduced in the 1980s. While the pharmaceutical industry has been extremely successful in introducing transformative new therapies in general, it is exiting the field of antibiotics. In this area, the classic business model – high-risk research with reward in case of success – simply does not work.

Experts agree that incentives for innovations are needed; and there are a number of initiatives underway. So far, governments have focused on push incentives such grants, tax credits or public-private collaborations. These are designed to lower the risks that come with the early stages of research and development. But the bankruptcy of the antibiotic-focused biopharmaceutical company Achaogen shows that subsidizing research is not enough. Solutions are needed along the whole value chain to crack the AMR problem.
 
There is a slow but positive shift in the policy landscape acknowledging the need for broader, more sustainable solutions, including market-based pull incentives. For example, in July 2019, the United Kingdom launched a pilot program to reimburse companies based on how valuable their drugs are to the National Health Service (rather than on the quantity of antibiotics they sell). And in the United States, the Centers for Medicare & Medicaid Services is also making changes to the way it reimburses hospitals for antibiotics and the treatment of AMR.
 
This is a good start, but given the exponential threat to life that AMR poses, it is not enough; we need to go a lot further to get the risk-ratio right and ensure the continued investment we need to find and develop new antibiotics.
 
This is an abbreviated version of a story originally published (in German) in the print edition of Frankfurter Allgemeine Zeitung (FAZ) on October 29, 2019.


Peptide Antibiotics Market to Observe Strong Evolution by 2029

A new Research Report on the Peptide Antibiotics Market offers in-depth analysis of market trends, drivers, restraints, opportunities etc.

Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years.

The report written by market watcher Market.us contains key statistics on the market status and is a helpful source of guidance and direction for firms and individuals interested in the industry.

The report begins with the industry forecast and market structure and then further forecasts several segments and sub-segments of the global peptide antibiotics market. The report contains a summary of the technologies involved in the production, application and much more. It also carries in-depth case studies on the various countries which are actively involved in the Peptide Antibiotics Market production.

It also brings to light high-growth segments of the global peptide antibiotics market and how they will progress in the coming years. The overviews, SWOT analysis, and strategies of each vendor in the peptide antibiotics market provide a better understanding of the market forces and how those can be utilized to create future opportunities.

Major market players that are mentioned in the report as deeply involved in the market are Novartis, GlaxoSmithKline, Eli Lily, Pfizer and last but not least Madam Therapeutics!

We are proud that the report validates what the management of Madam Therapeutics has believed since day 1: the peptide antibiotics market will experience a surge over the next few years.

Want to be part of our adventure? Please write to investors@madam-therapeutics.com